Kyongbo Pharmaceutical Co., Ltd
KRX:214390.KS
7440 (KRW) • At close March 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 216,357.482 | 196,264.902 | 170,659.645 | 215,285.095 | 191,706.189 | 201,343.596 | 191,661.374 | 186,726.17 | 178,032.632 | 169,781.246 |
| Cost of Revenue
| 155,276.343 | 151,847.03 | 135,299.352 | 162,820.355 | 150,990.036 | 152,082.417 | 137,038.683 | 142,622.767 | 129,475.387 | 119,975.881 |
| Gross Profit
| 61,081.139 | 44,417.872 | 35,360.293 | 52,464.74 | 40,716.153 | 49,261.178 | 54,622.691 | 44,103.403 | 48,557.245 | 49,805.365 |
| Gross Profit Ratio
| 0.282 | 0.226 | 0.207 | 0.244 | 0.212 | 0.245 | 0.285 | 0.236 | 0.273 | 0.293 |
| Reseach & Development Expenses
| 3,653.609 | 3,076.836 | 5,053.263 | 6,238.238 | 1,418.246 | 769.777 | 765.403 | 1,484.458 | 1,866.738 | 1,251.438 |
| General & Administrative Expenses
| 2,381.395 | 1,913.611 | 2,288.277 | 2,930.524 | 3,979.332 | 3,289.891 | 4,372.12 | 4,434.433 | 3,554.951 | 1,873.968 |
| Selling & Marketing Expenses
| 33,402.085 | 22,122.861 | 17,153.554 | 11,403.958 | 8,874.763 | 8,006.781 | 7,895.982 | 6,425.099 | 5,171.14 | 6,115.969 |
| SG&A
| 51,274.084 | 24,036.472 | 19,441.831 | 14,334.482 | 12,854.095 | 11,296.672 | 12,268.102 | 10,859.532 | 8,726.091 | 7,989.937 |
| Other Expenses
| -608.674 | 15,911.912 | 17,490.043 | 23,230.588 | 20,249.739 | 266.627 | 2,191.657 | 778.574 | 648.976 | 3,312.286 |
| Operating Expenses
| 55,536.367 | 43,025.22 | 41,985.137 | 43,803.308 | 34,522.08 | 31,994.604 | 30,036.042 | 28,509.176 | 22,924.91 | 22,136.802 |
| Operating Income
| 5,544.772 | 1,392.652 | -4,595.42 | 5,677.213 | 6,194.073 | 17,266.575 | 24,586.649 | 15,594.227 | 25,632.335 | 27,668.563 |
| Operating Income Ratio
| 0.026 | 0.007 | -0.027 | 0.026 | 0.032 | 0.086 | 0.128 | 0.084 | 0.144 | 0.163 |
| Total Other Income Expenses Net
| -2,996.52 | -2,007.488 | -5,337.527 | 8,353.58 | 788.081 | 376.973 | -325.611 | 48.859 | -100.026 | 2,365.742 |
| Income Before Tax
| 2,548.252 | -614.836 | -9,932.947 | 14,030.793 | 6,982.154 | 17,643.548 | 24,261.039 | 15,643.086 | 25,532.309 | 30,034.305 |
| Income Before Tax Ratio
| 0.012 | -0.003 | -0.058 | 0.065 | 0.036 | 0.088 | 0.127 | 0.084 | 0.143 | 0.177 |
| Income Tax Expense
| -802.476 | -1,225.426 | -2,437.768 | 4,626.346 | 1,696.914 | 4,527.498 | 6,297.729 | 2,937.156 | -577.314 | 21,398.351 |
| Net Income
| 2,974.4 | 610.59 | -7,495.179 | 9,404.446 | 5,285.239 | 13,116.049 | 17,963.31 | 12,705.93 | 26,109.623 | 8,635.954 |
| Net Income Ratio
| 0.014 | 0.003 | -0.044 | 0.044 | 0.028 | 0.065 | 0.094 | 0.068 | 0.147 | 0.051 |
| EPS
| 124.42 | 25.54 | -313.52 | 393.38 | 221.08 | 549 | 751 | 531 | 1,147 | 401 |
| EPS Diluted
| 124.42 | 25.54 | -313.52 | 393.38 | 221.08 | 549 | 751 | 531 | 1,147 | 401 |
| EBITDA
| 17,243.592 | 13,115.28 | 8,161.277 | 18,265.157 | 20,038.941 | 29,715.885 | 36,764.748 | 26,973.774 | 34,907.5 | 38,471.26 |
| EBITDA Ratio
| 0.08 | 0.067 | 0.048 | 0.085 | 0.105 | 0.148 | 0.192 | 0.144 | 0.196 | 0.227 |